Prognostic values of initial responses to low-dose 131I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma

Annals of Nuclear Medicine

Volumn 27, Issue 9, 2013, Pages 839-846

  Wakabayashi, Hiroshi ^a   Taki, Junichi ^a   Inaki, Anri ^a   Nakamura, Ayane ^a   Kayano, Daiki ^a   Fukuoka, Makoto ^a   Matsuo, Shinro ^a   Nakajima, Kenichi ^a   Kinuya, Seigo ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Initial response; Low dose of 131I MIBG; Malignant paraganglioma; Malignant pheochromocytoma; Radiotherapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; POTASSIUM IODIDE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CATECHOLAMINE EXCRETION; CATECHOLAMINE URINE LEVEL; CLINICAL ARTICLE; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; DECOMPRESSION SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; HYPERTENSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION EXPOSURE; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL TIME; SYMPTOM; THROMBOCYTE COUNT; TREATMENT RESPONSE;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROGNOSIS; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84890311276     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0755-z     Document Type: Article

References (14)

1. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 1984;25:197-206.
2. Carrasquillo JA, Pandit-Taskar N, Chen CC. Radionuclide therapy of adrenal tumors. J Surg Oncol. 2012;106:632-42.
3. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162-8.
4. 131I-MIBG). Ann N Y Acad Sci. 2006;1073:465-90.
5. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648-58.
6. Shilkrut M, Bar-Deroma R, Bar-Sela G, Berniger A, Kuten A. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience. Am J Clin Oncol. 2010;33:79-82.
7. Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, et al. (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging. 2010;54:100-13.
8. Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun. 2005;26:969-76.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
10. Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol. 2001;127:143-55.
11. Sisson JC, Shapiro B, Shulkin BL, Urba S, Zempel S, Spaulding S. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol. 1999;22:364-70.
12. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113:2020-8.
13. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab. 2009;94:2850-6.
14. Sisson JC, Shulkin BL, Esfandiari NH. Courses of malignant pheochromocytoma implications for therapy. Ann N Y Acad Sci. 2006;1073:505-11.